IL2 and neoplasm: T lymphocytes or T killer cells from either healthy [12] or tumor-bearing dogs [13] can be successfully expanded and activated ex vivo, with the aid of anti-CD3 antibody, IL-2, with or without other cytokines such as interferon α (IFN-α).